, Volume 68, Issue 13, pp 1803–1839 | Cite as

Approved and Investigational Uses of Modafinil

An Evidence-Based Review
Review Article


Modafinil is a wake-promoting agent that is pharmacologically different from other stimulants. It has been investigated in healthy volunteers, and in individuals with clinical disorders associated with excessive sleepiness, fatigue, impaired cognition and other symptoms. This review examines the use of modafinil in clinical practice based on the results of randomized, double-blind, placebo-controlled clinical trials available in the English language in the MEDLINE database. In sleep-deprived individuals, modafinil improves mood, fatigue, sleepiness and cognition to a similar extent as caffeine but has a longer duration of action. Evidence for improved cognition in non-sleep-deprived healthy volunteers is controversial.

Modafinil improves excessive sleepiness and illness severity in all three disorders for which it has been approved by the US FDA, i.e. narcolepsy, shift-work sleep disorder and obstructive sleep apnoea with residual excessive sleepiness despite optimal use of continuous positive airway pressure (CPAP). However, its effects on safety on the job and on morbidities associated with these disorders have not been ascertained. Continued use of CPAP in obstructive sleep apnoea is essential. Modafinil does not benefit cataplexy.

In very small, short-term trials, modafinil improved excessive sleepiness in patients with myotonic dystrophy. It was efficacious in fairly large studies of attention deficit hyperactivity disorder (ADHD) in children and adolescents, and was as efficacious as methylphenidate in a small trial, but has not been approved by the FDA, in part because of its serious dermatological toxicity. In a trial of 21 non-concurrent subjects, with 2-week treatment periods, modafinil was as effective as dexamfetamine in adult ADHD. Modafinil was helpful for depressive symptoms in bipolar disorder in a trial that excluded patients with stimulant-induced mania. A single dose of modafinil may hasten recovery from general anaesthesia after day surgery. A single dose of modafinil improved the ability of emergency room physicians to attend didactic lectures after a night shift, but did not improve their ability to drive home and caused sleep disturbances subsequently.

Modafinil had a substantial placebo effect on outcomes such as fatigue, excessive sleepiness and depression in patients with traumatic brain injury, major depressive disorder, schizophrenia, post-polio fatigue and multiple sclerosis; however, it did not provide any benefit greater than placebo.

Trials of modafinil for excessive sleepiness in Parkinson’s disease, cocaine addiction and cognition in chronic fatigue syndrome provided inconsistent results; all studies had extremely small sample sizes. Modafinil cannot be recommended for these conditions until definitive data become available.

Modafinil induces and inhibits several cytochrome P450 isoenzymes and has the potential for interacting with drugs from all classes. The modafinil dose should be reduced in the elderly and in patients with hepatic disease. Caution is needed in patients with severe renal insufficiency because of substantial increases in levels of modafinil acid. Common adverse events with modafinil include insomnia, headache, nausea, nervousness and hypertension. Decreased appetite, weight loss and serious dermatological have been reported with greater frequency in children and adolescents, probably due to the higher doses (based on bodyweight) used. Modafinil may have some abuse/addictive potential although no cases have been reported to date.


  1. 1.
    National Sleep Foundation. Omnibus sleep in America poll. Washington, DC: National Sleep Foundation, 2001Google Scholar
  2. 2.
    Hasler G, Buysse DJ, Gamma A, et al. Excessive daytime sleepiness in young adults: a 20-year prospective community study. J Clin Psychiatry 2005; 66: 521–9PubMedCrossRefGoogle Scholar
  3. 3.
    Pilcher JJ, Huffcutt AI. Effects of sleep deprivation on performance: a meta-analysis. Sleep 1996 May; 19(4): 318–2PubMedGoogle Scholar
  4. 4.
    Dinges DF, Pack F, Williams K, et al. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4–5 hours per night. Sleep 1997 Apr; 20(4): 267–77PubMedGoogle Scholar
  5. 5.
    Van Dongen HP, Maislin G, Mullington JM, et al. The cumulative cost of additional wakefulness: dose-response effects on neurobehavioral functions and sleep physiology from chronic sleep restriction and total sleep deprivation. Sleep 2003 Mar 15; 26(2): 117–26PubMedGoogle Scholar
  6. 6.
    NHTSA. National Highway Traffic Safety Administration report [online]. Available from URL: http://www.nhtsa.gov/people/injury/research/drowsy_driver.html [Accessed 2006 Apr 25]
  7. 7.
    Leger D. The cost of sleep-related accidents: a report for the National Commission on Sleep Disorders Research. Sleep 1994 Feb; 17(1): 84–93PubMedGoogle Scholar
  8. 8.
    Saper CB, Scammell TE, Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005 Oct 27; 437(7063): 1257–63PubMedCrossRefGoogle Scholar
  9. 9.
    Fuller PM, Gooley JJ, Saper CB. Neurobiology of the sleep-wake cycle: sleep architecture, circadian regulation, and regulatory feedback. J Biol Rhythms 2006 Dec; 21(6): 482–93PubMedCrossRefGoogle Scholar
  10. 10.
    Minzenberg MJ, Carter CS. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology 2008 Jun; 33(7): 1477–502PubMedCrossRefGoogle Scholar
  11. 11.
    Mignot E, Nishino S, Guilleminault C, et al. Modafinil binds to the dopamine uptake carrier site with low affinity. Sleep 1994 Aug; 17: 436–7PubMedGoogle Scholar
  12. 12.
    De Séréville JE, Boer C, Rambert FA, et al. Lack of pre-synaptic dopaminergic involvement in modafinil activity in anaesthetized mice: in vivo voltammetry studies. Neuropharmacology 1994 Jun; 33: 755–61PubMedCrossRefGoogle Scholar
  13. 13.
    Simon P, Hémet C, Ramassamy C, et al. Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice. Eur Neuropsychopharmacol 1995 Dec; 5(4): 509–14PubMedGoogle Scholar
  14. 14.
    Akaoka H, Roussel B, Lin JS, et al. Effect of modafinil and amphetamine on the rat catecholaminergic neuron activity. Neurosci Lett 1991 Feb 11; 123(1): 20–2PubMedCrossRefGoogle Scholar
  15. 15.
    Duteil J, Rambert FA, Pessonnier J, et al. Central alpha 1-adrenergic stimulation in relation to the behaviour stimulating effect of modafinil: studies with experimental animals. Eur J Pharmacol 1990 May 3; 180(1): 49–58PubMedCrossRefGoogle Scholar
  16. 16.
    Lin JS, Roussel B, Akaoka H, et al. Role of catecholamines in the modafinil and amphetamine induced wakefulness, a comparative pharmacological study in the cat. Brain Res 1992 Sep 25; 591(2): 319–26PubMedCrossRefGoogle Scholar
  17. 17.
    Eagle DM, Tufft MR, Goodchild HL, et al. Differential effects of modafinil and methylphenidate on stop-signal reaction time task performance in the rat, and interactions with the dopamine receptor antagonist cis-flupenthixol. Psychopharmacology (Berl) 2007 Jun; 192(2): 193–206CrossRefGoogle Scholar
  18. 18.
    de Saint Hilaire Z, Orosco M, Rouch C, et al. Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats. Neuroreport 2001 Nov 16; 12(16): 3533–7PubMedCrossRefGoogle Scholar
  19. 19.
    Wisor JP, Nishino S, Sora I, et al. Dopaminergic role in stimulant-induced wakefulness. J Neurosci 2001; 21: 1787–94PubMedGoogle Scholar
  20. 20.
    Murillo-Rodriguez E, Haro R, Palomero-Rivero M, et al. Modafinil enhances extracellular levels of dopamine in the nucleus accumbens and increases wakefulness in rats. Behav Brain Res 2007 Jan 25; 176(2): 353–7PubMedCrossRefGoogle Scholar
  21. 21.
    Dopheide MM, Morgan RE, Rodvelt KR, et al. Modafinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants. Eur J Pharmacol 2007 Jul 30; 568(1–3): 112–23PubMedCrossRefGoogle Scholar
  22. 22.
    Korotkova TM, Klyuch BP, Ponomarenko AA, et al. Modafinil inhibits rat midbrain dopaminergic neurons through D2-like receptors. Neuropharmacology 2007 Feb; 52(2): 626–33PubMedCrossRefGoogle Scholar
  23. 23.
    Madras BK, Xie Z, Lin Z, et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 2006 Nov; 319(2): 561–9PubMedCrossRefGoogle Scholar
  24. 24.
    Mignot E, Renaud A, Nishino S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl) 1993; 113(1): 76–82CrossRefGoogle Scholar
  25. 25.
    Nishino S, Fruhstorfer B, Arrigoni J, et al. Further characterization of the alpha-1 receptor subtype involved in the control of cataplexy in canine narcolepsy. J Pharmacol Exp Ther 1993 Mar; 264(3): 1079–84PubMedGoogle Scholar
  26. 26.
    Gallopin T, Luppi PH, Rambert FA, et al. Effect of the wake-promoting agent modafinil on sleep-promoting neurons from the ventrolateral preoptic nucleus: an in vitro pharmacologic study. Sleep 2004 Feb 1; 27(1): 19–25PubMedGoogle Scholar
  27. 27.
    Stone EA, Cotecchia S, Lin Y, et al. Role of brain alpha 1B-adrenoceptors in modafinil-induced behavioral activity. Synapse 2002 Dec 15; 46(4): 269–70PubMedCrossRefGoogle Scholar
  28. 28.
    Wisor JP, Eriksson KS. Dopaminergic-adrenergic interactions in the wake promoting mechanism of modafinil. Neuroscience 2005; 132: 1027–34PubMedCrossRefGoogle Scholar
  29. 29.
    Ferraro L, Antonelli T, O’Connor WT, et al. The antinarcoleptic drug modafinil increases glutamate release in thalamic areas and hippocampus. Neuroreport 1997 Sep 8; 8(13): 2883–7PubMedCrossRefGoogle Scholar
  30. 30.
    Ferraro L, Antonelli T, O’Connor WT, et al. The effects of modafinil on striatal, pallidal and nigral GABA and glutamate release in the conscious rat: evidence for a preferential inhibition of striato-pallidal GABA transmission. Neurosci Lett 1998 Sep 4; 253(2): 135–8PubMedCrossRefGoogle Scholar
  31. 31.
    Ferraro L, Tanganelli S, O’Connor WT, et al. The vigilance promoting drug modafinil decreases GABA release in the medial preoptic area and in the posterior hypothalamus of the awake rat: possible involvement of the serotonergic 5-HT3 receptor. Neurosci Lett 1996 Dec 6; 220: 5–8PubMedCrossRefGoogle Scholar
  32. 32.
    Ferraro L, Antonelli T, Tanganelli S, et al. The vigilance promoting drug modafinil increases extracellular glutamate levels in the medial preoptic area and the posterior hypothalamus of the conscious rat: prevention by local GABAA receptor blockade. Neuropsychopharmacology 1999 Apr; 20(4): 346–56PubMedCrossRefGoogle Scholar
  33. 33.
    Tanganelli S, Fuxe K, Ferraro L, et al. Inhibitory effects of the psychoactive drug modafinil on γ-aminobutyric acid outflow from the cerebral cortex of the awake freely moving guinea pig: possible involvement of 5-hydroxytryptamine mechanisms. Naunyn Schmiedebergs Arch Pharmacol 1992; 345: 461–5PubMedCrossRefGoogle Scholar
  34. 34.
    Tanganelli S, Ferraro L, Bianchi C, et al. 6-Hydroxy-dopamine treatment counteracts the reduction of cortical GABA release produced by the vigilance promoting drug modafinil in the awake freely moving guinea-pig. Neurosci Lett 1994 Apr 25; 171(1–2): 201–4PubMedCrossRefGoogle Scholar
  35. 35.
    Tanganelli S, Pérez de la Mora M, Ferraro L, et al. Modafinil and cortical gamma-aminobutyric acid outflow: modulation by 5-hydroxytryptamine neurotoxins. Eur J Pharmacol 1995 Jan 24; 273(1–2): 63–71PubMedCrossRefGoogle Scholar
  36. 36.
    Ferraro L, Tanganelli S, O’Connor WT, et al. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol 1996 Jun 13; 306: 33–9PubMedCrossRefGoogle Scholar
  37. 37.
    Ferraro L, Antonelli T, O’Connor WT, et al. Modafinil: an antinarcoleptic drug with a different neurochemical profile to d-amphetamine and dopamine uptake blockers. Biol Psychiatry 1997 Dec 15; 42(12): 1181–3PubMedCrossRefGoogle Scholar
  38. 38.
    Ferraro L, Fuxe K, Tanganelli S, et al. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology 2000 Aug 23; 39(11): 1974–83PubMedCrossRefGoogle Scholar
  39. 39.
    Ferraro L, Fuxe K, Tanganelli S, et al. Differential enhancement of dialysate serotonin levels in distinct brain regions of the awake rat by modafinil: possible relevance for wakefulness and depression. J Neurosci Res 2002 Apr 1; 68(1): 107–12PubMedCrossRefGoogle Scholar
  40. 40.
    Ferraro L, Fuxe K, Agnati L, et al. Modafinil enhances the increase of extracellular serotonin levels induced by the antidepressant drugs fluoxetine and imipramine: a dual probe microdialysis study in awake rat. Synapse 2005 Mar 15; 55(4): 230–41PubMedCrossRefGoogle Scholar
  41. 41.
    Nishino S. The hypocretin/orexin system in health and disease. Biol Psychiatry 2003 Jul 15; 54(2): 87–95PubMedCrossRefGoogle Scholar
  42. 42.
    Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999 Aug 20; 98(4): 437–51PubMedCrossRefGoogle Scholar
  43. 43.
    Scammell TE, Estabrooke IV, McCarthy MT, et al. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J Neurosci 2000 Nov 15; 20(22): 8620–8PubMedGoogle Scholar
  44. 44.
    Willie JT, Renthal W, Chemelli RM, et al. Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates. Neuroscience 2005; 130(4): 983–95PubMedCrossRefGoogle Scholar
  45. 45.
    Ishizuka T, Sakamoto Y, Sakurai T, et al. Modafinil increases histamine release in the anterior hypothalamus of rats. Neurosci Lett 2003 Mar 20; 339(2): 143–6PubMedCrossRefGoogle Scholar
  46. 46.
    Ishizuka T, Murakami M, Yamatodani A. Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats. Eur J Pharmacol 2008 Jan 14; 578(2–3): 209–15PubMedCrossRefGoogle Scholar
  47. 47.
    Lagarde D, Milhaud C. Electroencephalographic effects of modafinil, an alpha-1-adrenergic psychostimulant, on the sleep of rhesus monkeys. Sleep 1990 Oct; 13: 441–8PubMedGoogle Scholar
  48. 48.
    Shelton J, Nishino S, Vaught J, et al. Comparative effects of modafinil and amphetamine on daytime sleepiness and cataplexy of narcoleptic dogs. Sleep 1995 Dec; 18: 817–26PubMedGoogle Scholar
  49. 49.
    Touret M, Sallanon-Moulin M, Jouvet M. Awakening properties of modafinil without paradoxical sleep rebound: comparative study with amphetamine in the rat. Neurosci Lett 1995 Apr 7; 189: 43–6PubMedCrossRefGoogle Scholar
  50. 50.
    Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997 Nov; 283: 757–69PubMedGoogle Scholar
  51. 51.
    Panckeri KA, Schotland HM, Pack AI, et al. Modafinil decreases hypersomnolence in the English bulldog, a natural animal model of sleep-disordered breathing. Sleep 1996 Oct; 19: 626–31PubMedGoogle Scholar
  52. 52.
    Lin JS, Gervasoni D, Hou Y, et al. Effects of amphetamine and modafinil on the sleep/wake cycle during experimental hypersomnia induced by sleep deprivation in the cat. J Sleep Res 2000 Mar; 9(1): 89–96PubMedCrossRefGoogle Scholar
  53. 53.
    Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology 2003; 165: 260–9PubMedGoogle Scholar
  54. 54.
    Baranski JV, Pigeau R, Dinich P, et al. Effects of modafinil on cognitive and meta-cognitive performance. Hum Psychopharmacol 2004 Jul; 19(5): 323–32PubMedCrossRefGoogle Scholar
  55. 55.
    Müller U, Steffenhagen N, Regenthal R, et al. Effects of modafinil on working memory processes in humans. Psychopharmacology 2004; 177: 161–9PubMedCrossRefGoogle Scholar
  56. 56.
    Makris AP, Rush CR, Frederich RC, et al. Behavioral and subjective effects of d-amphetamine and modafinil in healthy adults. Exp Clin Psychopharmacol 2007 Apr; 15(2): 123–33PubMedCrossRefGoogle Scholar
  57. 57.
    Randall DC, Shneerson JM, Plaha KK, et al. Modafinil affects mood, but not cognitive function, in healthy young volunteers. Hum Psychopharmacol 2003; 18: 163–73PubMedCrossRefGoogle Scholar
  58. 58.
    Randall DC, Fleck NL, Shneerson JM, et al. The cognitive-enhancing properties of modafinil are limited in non-sleep-deprived middle-aged volunteers. Pharmacol Biochem Behav 2004; 77: 547–55PubMedCrossRefGoogle Scholar
  59. 59.
    Randall DC, Viswanath A, Bharania P, et al. Does modafinil enhance cognitive performance in young volunteers who are not sleep-deprived? J Clin Psychopharmacol 2005; 25: 175–9PubMedCrossRefGoogle Scholar
  60. 60.
    Taneja I, Haman K, Shelton RC, et al. A randomized, double-blind, crossover trial of modafinil on mood. J Clin Psychopharmacol 2007 Feb; 27(1): 76–9PubMedCrossRefGoogle Scholar
  61. 61.
    Lagarde D, Batejat D. Disrupted sleep-wake rhythm and performance: advantages of modafinil. Mil Psychol 1995; 7: 165–91CrossRefGoogle Scholar
  62. 62.
    Pigeau R, Naitoh P, Buguet A, et al. Modafinil, d-amphetamine and placebo during 64h of sustained mental work. I, effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res 1995; 4: 212–28Google Scholar
  63. 63.
    Stivalet P, Esquivie D, Barraud P-A, et al. Effects of modafinil on attentional processes during 60h of sleep deprivation. Hum Psychopharmacol 1998; 13: 501–7CrossRefGoogle Scholar
  64. 64.
    Wesensten NJ, Belenky G, Kautz MA, et al. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine. Psychopharmacology 2002; 159: 238–47PubMedCrossRefGoogle Scholar
  65. 65.
    Wesensten NJ, Belenky G, Thorne DR, et al. Modafinil vs. caffeine: effects on fatigue during sleep deprivation. Aviat Space Environ Med 2004 Jun; 75(6): 520–5Google Scholar
  66. 66.
    Wesensten NJ, Killgore WD, Balkin TJ. Performance and alertness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. J Sleep Res 2005 Sep; 14(3): 255–66PubMedCrossRefGoogle Scholar
  67. 67.
    Dinges DF, Arora S, Darwish M, et al. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Curr Med Res Opin 2006 Jan; 22(1): 159–67PubMedCrossRefGoogle Scholar
  68. 68.
    Lagarde D, Batejat D, Van Beers P, et al. Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Fundam Clin Pharmacol 1995; 9(3): 271–9PubMedCrossRefGoogle Scholar
  69. 69.
    Walsh JK, Randazzo AC, Stone KL, et al. Modafinil improves alertness, vigilance, and executive function during simulated night shifts. Sleep 2004 May 1; 27(3): 434–9PubMedGoogle Scholar
  70. 70.
    Hart CL, Haney M, Vosburg SK, et al. Modafinil attenuates disruptions in cognitive performance during simulated night-shift work. Neuropsychopharmacology 2006 Jul; 31(7): 1526–36PubMedCrossRefGoogle Scholar
  71. 71.
    Saletu B, Frey R, Krupka M, et al. Differential effects of a new adrenergic agonist: modafinil and D-amphetamine on sleep and early morning behaviour in young healthy volunteers. Int J Clin Pharmacol Res 1989; 9(3): 183–95PubMedGoogle Scholar
  72. 72.
    Saletu B, Frey R, Krupka M, et al. Differential effects of the new adrenergic agonist modafinil and D-amphetamine on sleep and early morning behaviour in eiderlies. Arzneimittelforschung 1989; 39(10): 1268–73PubMedGoogle Scholar
  73. 73.
    Robertson PR, Hellriegel ET. Clinical pharmacokinetic profile of modafinil. Clin Pharmacokinet 2003; 42(2): 123–7PubMedCrossRefGoogle Scholar
  74. 74.
    Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol 1999 Jan; 39(1): 30–40PubMedCrossRefGoogle Scholar
  75. 75.
    Wong YN, King SP, Simcoe D, et al. Open-label, single-dose pharmacokinetic study of modafinil tablets: influence of age and gender in normal subjects. J Clin Pharmacol 1999 Mar; 39(3): 281–8PubMedGoogle Scholar
  76. 76.
    Moachon G, Kanmacher I, Clenet M, et al. Pharmacokinetic profile of modafinil. Drugs Today 1996; 32: 327–37Google Scholar
  77. 77.
    Cephalon Inc. Provigil (modafinil) tablets: prescribing information [online]. Available from URL: http://www.provigil.com/ [Accessed 2007 Feb 22]
  78. 78.
    Billiard M, Besset A, Montplaisir J, et al. Modafinil: a double-blind multicentric study. Sleep 1994 Dec; 17 (8 Suppl.): S107–12PubMedGoogle Scholar
  79. 79.
    US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 1998 Jan; 43(1): 88–97CrossRefGoogle Scholar
  80. 80.
    US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 2000 Mar 14; 54(5): 1166–75CrossRefGoogle Scholar
  81. 81.
    Broughton RJ, Fleming JA, George CF, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 1997; 49: 444–51PubMedCrossRefGoogle Scholar
  82. 82.
    Schwartz JR, Feldman NT, Bogan RK, et al. Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy. Clin Neuropharmacol 2003 Sep–Oct; 26(5): 252–7PubMedCrossRefGoogle Scholar
  83. 83.
    Schwartz JR, Nelson MT, Schwartz ER, et al. Effects of modafinil on wakefulness and executive function in patients with narcolepsy experiencing late-day sleepiness [published erratum appears in Clin Neuropharmacol 2004 May–Jun; 27 (3): 152]. Clin Neuropharmacol 2004 Mar–Apr; 27(2): 74–9PubMedCrossRefGoogle Scholar
  84. 84.
    Guilleminault C, Abad VC. Obstructive sleep apnea syndromes. Med Clin North Am 2004 May; 88(3): 611–30PubMedCrossRefGoogle Scholar
  85. 85.
    Kingshott RN, Vennelle M, Coleman EL, et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of residual daytime excessive sleepiness in the sleep apnea/hypopneac syndrome. Am J Respir Crit Care Med 2001; 163: 918–23PubMedGoogle Scholar
  86. 86.
    Pack AI, Black JE, Schwartz JRL, et al. Modafinil as adjunct therapy for daytime sleepiness in the obstructive sleep apnea. Am J Respir Crit Care Med 2001; 164: 1675–81PubMedGoogle Scholar
  87. 87.
    Black JE, Hirshkowitz M. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome. Sleep 2005 Apr 1; 28(4): 464–71PubMedGoogle Scholar
  88. 88.
    Dinges D, Weaver TE. Effects of modafinil on sustained attention performance and quality of life in OSA patients with residual sleepiness while being treated with nCPAP. Sleep Medicine 2003; 4: 393–402PubMedCrossRefGoogle Scholar
  89. 89.
    Beers TM. Flexible schedules and shift work: replacing the ‘9-to-5’ workday? Monthly Labor Rev 2000; 123: 33–40Google Scholar
  90. 90.
    Drake CL, Roehrs T, Richardson G, et al. Shift work sleep disorder: prevalence and consequences beyond that of symptomatic day workers. Sleep 2004 Dec 15; 27(8): 1453–62PubMedGoogle Scholar
  91. 91.
    Czeisler CA, Walsh JK, Roth T, et al., for the U.S. Modafinil in Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with shift-work sleep disorder. N Engl J Med 2005 Aug 4; 353(5): 476–86PubMedCrossRefGoogle Scholar
  92. 92.
    Erman MK, Rosenberg R, for the US Modafinil Shift Work Sleep Disorder Study Group. Modafinil for excessive sleepiness associated with chronic shift work sleep disorder: effects on patient functioning and health-related quality of life. Prim Care Companion J Clin Psychiatry 2007; 9(3): 188–94PubMedCrossRefGoogle Scholar
  93. 93.
    Ondo WG, Fayle R, Atassi F, et al. Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 2005 Dec; 76(12): 1636–9PubMedCrossRefGoogle Scholar
  94. 94.
    Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled trial. Sleep 2002; 25: 905–9PubMedGoogle Scholar
  95. 95.
    Adler CH, Caviness JN, Hentz JG, et al. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease. Movement Disorders 2003; 18: 287–93PubMedCrossRefGoogle Scholar
  96. 96.
    Laberge L, Bégin P, Montplaisir J, et al. Sleep complaints in patients with myotonic dystrophy. J Sleep Res 2004 Mar; 13(1): 95–100PubMedCrossRefGoogle Scholar
  97. 97.
    MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology 2002; 59: 1876–80PubMedCrossRefGoogle Scholar
  98. 98.
    Talbot K, Stradling J, Crosby J, et al. Reduction in excess daytime sleepiness by modafinil in patients with myotonic dystrophy. Neuromuscul Disord 2003; 13: 357–64PubMedCrossRefGoogle Scholar
  99. 99.
    Wintzen AR, Lammers GJ, van Dijk JG. Does modafinil enhance activity of patients with myotonic dystrophy? A double-blind placebo-controlled crossover study. J Neurol 2007 Jan; 254(1): 26–8PubMedCrossRefGoogle Scholar
  100. 100.
    Jha A, Weintraub A, Allshouse A, et al. A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. J Head Trauma Rehabil 2008 Jan–Feb; 23(1): 52–63PubMedCrossRefGoogle Scholar
  101. 101.
    Visser SN, Lesesne CA. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder: United States, 2003. MMWR Morb Mortal Wkly Rep 2005; 54(34): 842–7Google Scholar
  102. 102.
    Biederman J, Swanson JM, Wigal SB, et al. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics 2005 Dec; 116(6): e777–84PubMedCrossRefGoogle Scholar
  103. 103.
    Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry 2006 Jan; 67(1): 137–47PubMedCrossRefGoogle Scholar
  104. 104.
    Greenhill LL, Biederman J, Boellner SW, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2006 May; 45(5): 503–11PubMedCrossRefGoogle Scholar
  105. 105.
    DuPaul G, Power T, Anastopoulos A, et al. ADHD rating scale-IV: home and school versions. New York: Guilford Publications, 1998Google Scholar
  106. 106.
    Conners CK. Conners’ parent rating scales-revised: short form (CPRS-R:S). North Tonawanda (NY): Multi-Health Systems, 1997Google Scholar
  107. 107.
    Gresham FM, Elliot SN. Social skills rating scale. Circle Pines (MN): American Guidance Service, 1990Google Scholar
  108. 108.
    Landgraf JM, Abetz L, Ware JE. The child health questionnaire (CHQ): a user’s manual. Boston (MA): Health Act, 1999Google Scholar
  109. 109.
    Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Psychopharmacologic Drugs Advisory Committee Meeting: March 2006 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/06/transcripts/2006-4212T1.pdf [Accessed 2007 Feb 24]
  110. 110.
    Biederman J, Swanson JM, Wigal SB, et al. Modafinil ADHD Study Group. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. J Clin Psychiatry 2006 May; 67(5): 727–35Google Scholar
  111. 111.
    Conners CK, Sitarenios G, Parker JD, et al. The revised Conners’ Parent Rating Scale (CPRS-R): factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998 Aug; 26(4): 257–68PubMedCrossRefGoogle Scholar
  112. 112.
    Amiri S, Mohammadi MR, Mohammadi M, et al. Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: a double blind, randomized clinical trial. Prog Neuropsychopharmacol Biol Psychiatry 2008 Jan 1; 32(1): 145–9PubMedCrossRefGoogle Scholar
  113. 113.
    Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006 Feb; 36(2): 159–65PubMedCrossRefGoogle Scholar
  114. 114.
    Moss SB, Nair R, Vallarino A, et al. Attention deficit/hyperactivity disorder in adults. Prim Care 2007 Sep; 34(3): 445–73PubMedCrossRefGoogle Scholar
  115. 115.
    Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. J Child Adolesc Psychopharmacol 2000; 10(4): 311–20PubMedCrossRefGoogle Scholar
  116. 116.
    Murphy KR, Barkley RA. Updated adult norms for the ADHD Behavior Checklist for Adults. ADHD Report 1996; 4: 12–13Google Scholar
  117. 117.
    Barkley RA, Murphy KR. Attention-deficit hyperactivity disorder: a clinical workbook. New York (NY): Guilford Press, 1998: 131–3Google Scholar
  118. 118.
    Golden CJ. Identification of brain disorders by the Stroop Color and Word Test. J Clin Psychol 1976; 32: 654–8PubMedCrossRefGoogle Scholar
  119. 119.
    Kessler RC, Berglund P, Dernier O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593–602PubMedCrossRefGoogle Scholar
  120. 120.
    Fava M, Thase ME, DeBattista C. A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005 Jan; 66(1): 85–93PubMedCrossRefGoogle Scholar
  121. 121.
    DeBattista C, Dogramji K, Menza MA, et al. Adjunct modafinil for short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry 2003; 64: 1057–64PubMedCrossRefGoogle Scholar
  122. 122.
    Dunlop BW, Crits-Christoph P, Evans DL, et al. Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study. J Clin Psychopharmacol 2007 Dec; 27(6): 614–9PubMedCrossRefGoogle Scholar
  123. 123.
    Frye MA, Grunze H, Suppes T, et al. A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression. Am J Psychiatry 2007 Aug; 164(8): 1242–9PubMedCrossRefGoogle Scholar
  124. 124.
    Rush AJ, Giles DE, Schlesser MA. The Inventory of Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 1986; 18: 65–87PubMedCrossRefGoogle Scholar
  125. 125.
    Turner DC, Clark L, Pomarol-Clotet E, et al. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology 2004 Jul; 29(7): 1363–73PubMedCrossRefGoogle Scholar
  126. 126.
    Sevy S, Rosenthal MH, Alvir J, et al. Double-blind, placebo-controlled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J Clin Psychiatry 2005 Jul; 66(7): 839–43PubMedCrossRefGoogle Scholar
  127. 127.
    Spence SA, Green RD, Wilkinson ID, et al. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br J Psychiatry 2005 Jul; 187: 55–61PubMedCrossRefGoogle Scholar
  128. 128.
    Pierre JM, Peloian JH, Wirshing DA, et al. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J Clin Psychiatry 2007 May; 68(5): 705–10PubMedCrossRefGoogle Scholar
  129. 129.
    Cambridge Neuropsychological Test Automated Battery (CANTAB®) [online]. Available from URL: http://www.cantab.com [Accessed 2007 Nov 1]
  130. 130.
    Callicott JH, Ramsey NF, Tallent K, et al. Functional magnetic resonance brain mapping in psychiatry: methodological issues illustrated in a study of working memory in schizophrenia. Neuropsychopharmacology 1998; 18: 186–96PubMedCrossRefGoogle Scholar
  131. 131.
    Overall JE, Gorham DR. The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988; 24: 97–9Google Scholar
  132. 132.
    Andreasen NC. Scale for the Assessment of Negative Symptoms (SANS). Br J Psychiatry 1989; 155 Suppl. 7: 53–8Google Scholar
  133. 133.
    Guy W, editor. ECDEU assessment manual for psychopharmacology. US Dept Health, Education and Welfare publication (ADM): Rockville (MD): National Institute of Mental Health, 1976: 76–338Google Scholar
  134. 134.
    Simpson GM, Lee JH, Zoubok B, et al. A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 1979; 64: 171–9CrossRefGoogle Scholar
  135. 135.
    Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–9PubMedCrossRefGoogle Scholar
  136. 136.
    Cornblatt BA, Lenzenweger MF, Erlenmeyer-Kimling L. The continuous performance test, identical pairs version: II, contrasting attentional profiles in schizophrenic and depressed patients. Psychiatry Res 1989 Jul; 29(1): 65–85PubMedCrossRefGoogle Scholar
  137. 137.
    Cornblatt BA, Obuchowski M, Roberts S, et al. Cognitive and behavioral precursors of schizophrenia. Dev Psychopathol 1999; 11: 487–508PubMedCrossRefGoogle Scholar
  138. 138.
    Gold JM, Carpenter C, Randolph C, et al. Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997 Feb; 54(2): 159–65PubMedCrossRefGoogle Scholar
  139. 139.
    Hershey T, Craft S, Glauser TA, et al. Short-term and long-term memory in early temporal lobe dysfunction. Neuropsychology 1998 Jan; 12(1): 52–64PubMedCrossRefGoogle Scholar
  140. 140.
    Lezak MD. Neuropsychological assessment. Third edition. New York (NY): Oxford University Press, 1995: 438–45, 544–50Google Scholar
  141. 141.
    Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch Gen Psychiatry 1982 Jul; 39(7): 784–8PubMedCrossRefGoogle Scholar
  142. 142.
    Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 2005 Jan; 30(1): 205–11PubMedCrossRefGoogle Scholar
  143. 143.
    Hart CL, Haney M, Vosburg SK, et al. Smoked cocaine self-administration is decreased by modafinil. Neuropsychopharmacology 2008 Mar; 33(4): 761–8PubMedCrossRefGoogle Scholar
  144. 144.
    Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Allen J, Litten RZ, editors. Measuring alcohol consumption: psychosocial and biological medthods. Totowa (NJ): Humana Press, 1992: 41–72Google Scholar
  145. 145.
    Kampman KM, Volpicelli JR, McGinnis DE, et al. Reliability and validity of the cocaine selective severity assessment. Addict Behav 1998; 23: 449–61PubMedCrossRefGoogle Scholar
  146. 146.
    Somoza E, Dyrenforth S, Goldsmith J, et al. In search of a universal drug craving scale. Annual Meeting of the American Psychiatric Association; 1995 May 20–25; Miami (FL)Google Scholar
  147. 147.
    Tiffany ST, Singleton E, Haertzen CA, et al. The development of a cocaine craving questionnaire. Drug Alcohol Depend 1993; 34: 19–28PubMedCrossRefGoogle Scholar
  148. 148.
    Randall DC, Cafferty FH, Shneerson JM, et al. Chronic treatment with modafinil may not be beneficial in patients with chronic fatigue syndrome. J Psychopharmacol 2005 Nov; 19(6): 647–60PubMedCrossRefGoogle Scholar
  149. 149.
    Chan KM, Strohschein FJ, Rydz D, et al. Randomized controlled trial of modafinil for the treatment of fatigue in post-polio syndrome. Muscle Nerve 2006 Jan; 33(1): 138–41PubMedCrossRefGoogle Scholar
  150. 150.
    Vasconcelos OM, Prokhorenko OA, Salajegheh MK, et al. Modafinil for treatment of fatigue in post-polio syndrome: a randomized controlled trial. Neurology 2007 May 15; 68(20): 1680–6PubMedCrossRefGoogle Scholar
  151. 151.
    Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. French Modafinil Study Group. Neurology 2005 Apr 12; 64(7): 1139–43Google Scholar
  152. 152.
    Larijani GE, Goldberg ME, Hojat M, et al. Modafinil improves recovery after general anesthesia. Anesth Analg 2004 Apr; 98(4): 976–81PubMedCrossRefGoogle Scholar
  153. 153.
    Gill M, Haerich P, Westcott K, et al. Cognitive performance following modafinil versus placebo in sleep-deprived emergency physicians: a double-blind randomized crossover study. Acad Emerg Med 2006 Feb; 13(2): 158–65PubMedCrossRefGoogle Scholar
  154. 154.
    Jasinski DR. An evaluation of the abuse potential of modafinil using methylphenidate as a reference. J Psychopharmacol 2000 Mar; 14(1): 53–60PubMedCrossRefGoogle Scholar
  155. 155.
    Martin WR, Sloan JW, Sapira JD, et al. Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 1971 Mar–Apr; 12(2): 245–58PubMedGoogle Scholar
  156. 156.
    Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004 Apr; 25(4): 193–200PubMedCrossRefGoogle Scholar
  157. 157.
    Robertson P, DeCory HH, Madan A, et al. In vitro inhibition and induction of human hepatic cytochrome P450 enzymes by modafinil. Drug Metab Dispos 2000 Jun; 28(6): 664–71PubMedGoogle Scholar
  158. 158.
    Robertson Jr P, Hellriegel ET, Arora S, et al. Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002 Feb; 42(2): 205–14PubMedCrossRefGoogle Scholar
  159. 159.
    Robertson Jr P, Hellriegel ET, Arora S, et al. Effect of modafinil on the pharmacokinetics of ethinyl estradiol and triazolam in healthy volunteers. Clin Pharmacol Ther 2002 Jan; 71(1): 46–56PubMedCrossRefGoogle Scholar
  160. 160.
    FDA. Provigil® (modafinil) tablets (C-IV) [online]. Available from URL: http://www.fda.gov/cder/foi/label/2004/20717sel008_provigil_lbl.pdf [Accessed 2007 Mar 3]
  161. 161.
    Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005 May 26; 352(21): 2211–21PubMedCrossRefGoogle Scholar
  162. 162.
    Bernard S, Neville KA, Nguyen AT, et al. Interethnic differences in genetic polymorphisms of CYP2D6 in the US population: clinical implications. Oncologist 2006 Feb; 11(2): 126–35PubMedCrossRefGoogle Scholar
  163. 163.
    Mariani JJ, Hart CL. Psychosis associated with modafinil and shift work [letter]. Am J Psychiatry 2005 Oct; 162(10): 1983PubMedCrossRefGoogle Scholar
  164. 164.
    Narendran R, Young CM, Valenti AM, et al. Is psychosis exacerbated by modafinil? Arch Gen Psychiatry 2002 Mar; 59(3): 292–3PubMedCrossRefGoogle Scholar
  165. 165.
    Sabatine MS, Poh KK, Mega JL, et al. Case records of the Massachusetts General Hospital: case 36-2007-a 31-year-old woman with rash, fever, and hypotension. N Engl J Med 2007 Nov 22; 357(21): 2167PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Department of Family MedicineUniversity of ChicagoChicagoUSA

Personalised recommendations